BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El Sagheer G, Soliman E, Ahmad A, Hamdy L. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs. Libyan J Med. 2018;13:1435124. [PMID: 29451090 DOI: 10.1080/19932820.2018.1435124] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Lin C, Chen J, Lee P, Tung H, Cheng C, Kao H, Wu Y, Pang M, Chuang T. Lipid profile changes after direct acting antiviral treatment in different genotypes of chronic hepatitis C virus‐infected patients. Adv in Digestive Med 2021;8:139-45. [DOI: 10.1002/aid2.13211] [Reference Citation Analysis]
2 Yosef T, Ibrahim WA, El-ghandour A, Attia S, El-nakeep S. Effect of different direct-acting antiviral regimens for treatment of nondiabetic hepatitis C virus–infected Egyptian patients on insulin resistance and sensitivity. Egypt J Intern Med 2021;33. [DOI: 10.1186/s43162-021-00075-8] [Reference Citation Analysis]
3 Nevola R, Rinaldi L, Zeni L, Sasso FC, Pafundi PC, Guerrera B, Marrone A, Giordano M, Adinolfi LE. Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct-acting antivirals. JGH Open. 2020;4:713-721. [PMID: 32782961 DOI: 10.1002/jgh3.12324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Isaac A, Elmarashly B, El Saeed K, Mohamed RS, Ibrahim SA, Safwat E. The effect of hepatitis C virologic clearance on cardiovascular disease biomarker lipoprotein-associated phospholipase A2 and its relation to serum lipids. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00110-x] [Reference Citation Analysis]
5 Shawky MA, Mohammed AQ, Hassan AM, Ali BH, Moustafa HM. Insulin resistance in nondiabetic Egyptian patients with chronic hepatitis C virus. Rev Gastroenterol Mex (Engl Ed) 2020;85:173-9. [PMID: 31784195 DOI: 10.1016/j.rgmx.2019.05.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol 2021; 27(29): 4831-4845 [PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831] [Reference Citation Analysis]
7 Alaarag AF, Hamam AM, Amin OA. The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction. Glob Heart 2021;16:3. [PMID: 33598383 DOI: 10.5334/gh.906] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Abdel Fattah NK, Shaheen SM, Ahmed OA, Elsaeed K, Sabri NA. Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals. F1000Res 2022;11:649. [DOI: 10.12688/f1000research.109397.1] [Reference Citation Analysis]
9 Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol 2018;2018:6150861. [PMID: 30186821 DOI: 10.1155/2018/6150861] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
10 Mansour-Ghanaei F, Joukar F, Naghipour M, Hassanipour S, Yeganeh S, Sepehrimanesh M, Fathalipour M. Epidemiologic profile of viral hepatitis B and C in North of Iran: results from PERSIAN Guilan Cohort Study (PGCS). BMC Res Notes 2021;14:59. [PMID: 33568187 DOI: 10.1186/s13104-021-05474-2] [Reference Citation Analysis]
11 Russo FP, Zanetto A, Gambato M, Bortoluzzi I, Al Zoairy R, Franceschet E, De Marchi F, Marzi L, Lynch EN, Floreani A, Farinati F, Schaefer B, Burra P, Zoller H, Mega A. Hepatitis C virus eradication with direct-acting antiviral improves insulin resistance. J Viral Hepat 2020;27:188-94. [PMID: 31596996 DOI: 10.1111/jvh.13215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Cárdaba-García ME, Abad-Lecha E, Calleja-Hernández MÁ. Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment. Libyan J Med 2021;16:1949797. [PMID: 34308801 DOI: 10.1080/19932820.2021.1949797] [Reference Citation Analysis]
14 Goñi Esarte S, Juanbeltz R, Zozaya JM, Úriz JI, Castilla J, Herrero JI. Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents. Gastroenterol Hepatol 2020;43:248-55. [PMID: 32192765 DOI: 10.1016/j.gastrohep.2019.03.017] [Reference Citation Analysis]
15 Elhelbawy M, Abdel-Razek W, Alsebaey A, Hashim M, Elshenawy H, Waked I. Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment. Eur J Gastroenterol Hepatol 2019;31:16-23. [PMID: 30024489 DOI: 10.1097/MEG.0000000000001215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Villani R, Di Cosimo F, Romano AD, Sangineto M, Serviddio G. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Sci Rep 2021;11:13944. [PMID: 34230541 DOI: 10.1038/s41598-021-93251-3] [Reference Citation Analysis]